These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 1716612)
41. [Ribosomal dysentery vaccine. III. An immunochemical and serological study]. Subbotina IuL; Levenson VI; Gofman IL Zh Mikrobiol Epidemiol Immunobiol; 1979 May; (5):44-52. PubMed ID: 110015 [TBL] [Abstract][Full Text] [Related]
42. Studies on acquired systemic resistance in mice with oral immunization with Shigella sonnei. Kowalewska D; Wieczorek Z Arch Immunol Ther Exp (Warsz); 1980; 28(2):345-55. PubMed ID: 7004395 [TBL] [Abstract][Full Text] [Related]
43. Technological aspect of the production of live dysentery vaccines for oral administration. Denchev V; Nenkov P; Vitanov T; Sumerska T; Marinova S; Vassilev T; Panova I; Bratoeva M; Linde K Acta Microbiol Hung; 1991; 38(2):121-6. PubMed ID: 1805499 [TBL] [Abstract][Full Text] [Related]
44. Immunity of the guinea pig's eye after vaccination with Shigella sonnei phase I antigen. Kerekes L Acta Microbiol Acad Sci Hung; 1976; 23(4):353-8. PubMed ID: 799899 [TBL] [Abstract][Full Text] [Related]
45. [Nonspecific nature of antibody formation suppression by virulent Shigella sonnei]. Borisov VA; Frolov AF Mikrobiol Zh (1978); 1982; 44(1):71-6. PubMed ID: 7040918 [No Abstract] [Full Text] [Related]
46. [Significance of bacteremia in the development of immunological memory suppression in Shigella sonnei infection in mice]. Frolov AF; Borisov VA Zh Mikrobiol Epidemiol Immunobiol; 1984 Apr; (4):97-101. PubMed ID: 6377773 [TBL] [Abstract][Full Text] [Related]
47. Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children. Ashkenazi S; Passwell JH; Harlev E; Miron D; Dagan R; Farzan N; Ramon R; Majadly F; Bryla DA; Karpas AB; Robbins JB; Schneerson R J Infect Dis; 1999 Jun; 179(6):1565-8. PubMed ID: 10228084 [TBL] [Abstract][Full Text] [Related]
48. A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection. Phalipon A; Tanguy M; Grandjean C; Guerreiro C; Bélot F; Cohen D; Sansonetti PJ; Mulard LA J Immunol; 2009 Feb; 182(4):2241-7. PubMed ID: 19201878 [TBL] [Abstract][Full Text] [Related]
49. Shigella sonnei vaccine candidates WRSs2 and WRSs3 are as immunogenic as WRSS1, a clinically tested vaccine candidate, in a primate model of infection. Barnoy S; Baqar S; Kaminski RW; Collins T; Nemelka K; Hale TL; Ranallo RT; Venkatesan MM Vaccine; 2011 Aug; 29(37):6371-8. PubMed ID: 21596086 [TBL] [Abstract][Full Text] [Related]
50. Construction of a stable and non-resistant bivalent vaccine candidate strain against Shigella flexneri 2a and Shigella sonnei. Rui X; Xu Y; Wan H; Su G; Huang C Chin J Biotechnol; 1996; 12(2):89-97. PubMed ID: 8988355 [TBL] [Abstract][Full Text] [Related]
51. Development, Interlaboratory Evaluations, and Application of a Simple, High-Throughput Nahm MH; Yu J; Weerts HP; Wenzel H; Tamilselvi CS; Chandrasekaran L; Pasetti MF; Mani S; Kaminski RW mSphere; 2018 Jun; 3(3):. PubMed ID: 29898979 [No Abstract] [Full Text] [Related]
59. Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease. Herrington DA; Van de Verg L; Formal SB; Hale TL; Tall BD; Cryz SJ; Tramont EC; Levine MM Vaccine; 1990 Aug; 8(4):353-7. PubMed ID: 2204243 [TBL] [Abstract][Full Text] [Related]
60. [Trial of the protective activity of ribosomal Sonne vaccine in monkeys]. Levenson VI; Dzhikidze EK; Stasilevich ZK; Kavtaradze KN; Subbotina IuL Vestn Akad Med Nauk SSSR; 1986; (3):69-72. PubMed ID: 3518271 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]